Q1 FY27 results, CMD re-appointment and final dividend record date

Management Changes View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+20.5%Reaction day

₹57.40

prior close

₹69.18

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+20.1% vs market

Pharmaceuticals peers, median of 165sector-0.0%+20.6% vs sector

On the reaction day the stock moved 20.1 pts more than Nifty Microcap 250 and 20.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+20.5+0.4+20.1-0.0+20.6

Next day

+33.6+1.7+31.9+0.0+33.6

+38.6+2.1+36.5+0.2+38.4

+39.4+2.1+37.3+0.4+39.0

+39.5+2.1+37.5+0.6+38.9

+33.8+1.9+31.9+0.8+33.0

+41.6+2.4+39.2+0.4+41.3

15d

+63.4+3.0+60.4+0.5+63.0

+97.9+3.7+94.2+1.0+96.9

+136.4+1.6+134.9+2.0+134.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Labs Q1 FY27 consolidated revenue rose to Rs 570.13 cr from Rs 425.24 cr YoY. Net profit jumped to Rs 56.40 cr from Rs 10.75 cr YoY, EPS Rs 1.03. Board re-appointed promoter Sushil Suri as CMD for 3 more years till Oct 2029, subject to AGM approval. Record date Sep 19 for final dividend. AGM on Sep 26.

Likely market impact

Strong Q1 profit growth and leadership continuity. Shareholder approvals pending for re-appointment and dividend.